Akero Therapeutics Inc (AKRO)
18.93
-1.33
(-6.56%)
USD |
NASDAQ |
Apr 25, 16:00
18.92
-0.01
(-0.05%)
After-Hours: 20:00
Akero Therapeutics Net Income (Quarterly): -55.19M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -55.19M |
September 30, 2023 | -39.66M |
June 30, 2023 | -31.08M |
March 31, 2023 | -25.83M |
December 31, 2022 | -23.06M |
September 30, 2022 | -35.54M |
June 30, 2022 | -27.40M |
March 31, 2022 | -26.03M |
December 31, 2021 | -32.42M |
September 30, 2021 | -24.33M |
June 30, 2021 | -28.93M |
March 31, 2021 | -15.09M |
Date | Value |
---|---|
December 31, 2020 | -29.71M |
September 30, 2020 | -21.40M |
June 30, 2020 | -16.21M |
March 31, 2020 | -11.89M |
December 31, 2019 | -15.61M |
September 30, 2019 | -15.55M |
June 30, 2019 | -7.228M |
March 31, 2019 | -5.362M |
December 31, 2018 | -61.47M |
September 30, 2018 | -11.15M |
June 30, 2018 | -8.673M |
March 31, 2018 | -0.421M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-55.19M
Minimum
Dec 2023
-7.228M
Maximum
Jun 2019
-25.38M
Average
-25.83M
Median
Mar 2023
Net Income (Quarterly) Benchmarks
Madrigal Pharmaceuticals Inc | -112.19M |
89bio Inc | -40.24M |
Viking Therapeutics Inc | -27.36M |
Eli Lilly and Co | 2.190B |
Ionis Pharmaceuticals Inc | -9.263M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 61.87M |
EPS Diluted (Quarterly) | -1.02 |
Enterprise Value | 780.13M |
Earnings Yield | -15.21% |